Evidence map›Paper›PMID 24829560›Full record

ReviewFrontiers in endocrinology2014

Mechanisms linking excess adiposity and carcinogenesis promotion.

Ana I Pérez-Hernández, Victoria Catalán, Javier Gómez-Ambrosi, Amaia Rodríguez, Gema Frühbeck

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Change in Inflammatory Biomarkers and Adipose Tissue inCancer prevention research (Philadelphia, Pa.) · 2018
    Trial
  3. Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Review
  4. Review
  5. Review
  6. Is Adipose Tissue Inflammation the Culprit of Obesity-Associated Comorbidities?Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines.International journal of molecular sciences · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana I Pérez-HernándezMetabolic Research Laboratory, Clínica Universidad de Navarra , Pamplona , Spain.
Victoria CatalánMetabolic Research Laboratory, Clínica Universidad de Navarra , Pamplona , Spain ; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III , Madrid , Spain.
Javier Gómez-AmbrosiMetabolic Research Laboratory, Clínica Universidad de Navarra , Pamplona , Spain ; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III , Madrid , Spain.
Amaia RodríguezMetabolic Research Laboratory, Clínica Universidad de Navarra , Pamplona , Spain ; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III , Madrid , Spain.
Gema FrühbeckMetabolic Research Laboratory, Clínica Universidad de Navarra , Pamplona , Spain ; Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III , Madrid , Spain ; Department of Endocrinology and Nutrition, Clínica Universidad de Navarra , Pamplona , Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity constitutes one of the most important metabolic diseases being associated to insulin resistance development and increased cardiovascular risk. Association between obesity and cancer has also been well established for several tumor types, such as breast cancer in post-menopausal women, colorectal, and prostate cancer. Cancer is the first death cause in developed countries and the second one in developing countries, with high incidence rates around the world. Furthermore, it has been estimated that 15-20% of all cancer deaths may be attributable to obesity. Tumor growth is regulated by interactions between tumor cells and their tissue microenvironment. In this sense, obesity may lead to cancer development through dysfunctional adipose tissue and altered signaling pathways. In this review, three main pathways relating obesity and cancer development are examined: (i) inflammatory changes leading to macrophage polarization and altered adipokine profile; (ii) insulin resistance development; and (iii) adipose tissue hypoxia. Since obesity and cancer present a high prevalence, the association between these conditions is of great public health significance and studies showing mechanisms by which obesity lead to cancer development and progression are needed to improve prevention and management of these diseases.

Indexed as

adipokineadipose tissuecarcinogenesishypoxiainflammationinsulin resistanceobesity

Identifiers

PMID24829560
PMCPMC4013474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.